Patents by Inventor Eric E. Swayze

Eric E. Swayze has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS FOR MODULATING TAU EXPRESSION
    Publication number: 20230323351
    Abstract: Disclosed herein are antisense compounds and methods for decreasing Tau mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate Tau-associated diseases, disorders, and conditions.
    Type: Application
    Filed: January 18, 2023
    Publication date: October 12, 2023
    Applicant: Biogen MA Inc.
    Inventors: Holly Kordasiewicz, Eric E. Swayze, Susan M. Freier, Huynh-Hoa Bui
  • Modulators of PCSK9 Expression
    Publication number: 20230321255
    Abstract: The present embodiments provide methods, compounds, and compositions useful for inhibiting PCSK9 expression, which may be useful for treating, preventing, or ameliorating a disease associated with PCSK9.
    Type: Application
    Filed: February 20, 2023
    Publication date: October 12, 2023
    Inventors: Eric E. SWAYZE, Susan M. FREIER, Huynh-Hoa BUI
  • Oligomeric Compounds Comprising Bicyclic Nucleotides and Uses Thereof
    Publication number: 20230279396
    Abstract: The present invention provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.
    Type: Application
    Filed: December 16, 2022
    Publication date: September 7, 2023
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Eric E. Swayze
  • Compositions and methods for modulating complement factor B expression
    Patent number: 11732265
    Abstract: The present embodiments provide methods, compounds, and compositions for treating, preventing, or ameliorating a disease associated with dysregulation of the complement alternative pathway by administering a Complement Factor B (CFB) specific inhibitor to a subject.
    Type: Grant
    Filed: May 7, 2021
    Date of Patent: August 22, 2023
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Tamar R. Grossman, Michael L. McCaleb, Andrew T. Watt, Susan M. Freier
  • Selective antisense compounds and uses thereof
    Patent number: 11732261
    Abstract: The present invention provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.
    Type: Grant
    Filed: September 3, 2020
    Date of Patent: August 22, 2023
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Punit P. Seth, Michael Oestergaard, Eric E. Swayze
  • MODIFIED CRISPR RNA AND MODIFIED SINGLE CRISPR RNA AND USES THEREOF
    Publication number: 20230159919
    Abstract: The present disclosure provides compounds comprising modified oligonucleotides for use in CRISPR. In certain embodiments, such modified oligonucleotides provide improved properties of crRNA. In certain embodiments, such modified oligonucleotides provide improved properties of scrRNA.
    Type: Application
    Filed: June 27, 2022
    Publication date: May 25, 2023
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Meghdad Rahdar, Thazha P. Prakash, Eric E. Swayze, C. Frank Bennett
  • COMPOSITIONS AND METHODS OF INHIBITING SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
    Publication number: 20230151366
    Abstract: The present embodiments provide methods, compounds, and compositions useful for inhibiting or reducing SARS-CoV-2 replication, infectivity, viral titer, or viral load, which can be useful for preventing or treating COVID-19 in an individual.
    Type: Application
    Filed: April 16, 2021
    Publication date: May 18, 2023
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Eric E. Swayze, Robert J. Prill
  • COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION
    Publication number: 20230151365
    Abstract: Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine.
    Type: Application
    Filed: October 21, 2022
    Publication date: May 18, 2023
    Applicant: IONIS PHARMACEUTICALS, INC.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
  • Modulators of PCSK9 expression
    Patent number: 11633483
    Abstract: The present embodiments provide methods, compounds, and compositions useful for inhibiting PCSK9 expression, which may be useful for treating, preventing, or ameliorating a disease associated with PCSK9.
    Type: Grant
    Filed: November 20, 2020
    Date of Patent: April 25, 2023
    Assignee: IONIS PHARMACEUTICALS, INC.
    Inventors: Eric E. Swayze, Susan M. Freier, Huynh-Hoa Bui
  • Oligomeric Compounds Comprising Bicyclic Nucleotides and Uses Thereof
    Publication number: 20230121967
    Abstract: The present invention provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.
    Type: Application
    Filed: April 6, 2022
    Publication date: April 20, 2023
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Eric E. Swayze
  • COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSION
    Publication number: 20230118177
    Abstract: The present embodiments provide methods, compounds, and compositions for treating, preventing, or ameliorating a disease associated with excess growth hormone using antisense compounds or oligonucleotides targeted to growth hormone receptor (GHR).
    Type: Application
    Filed: March 7, 2022
    Publication date: April 20, 2023
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Sanjay Bhanot, Susan M. Freier, Huynh-Hoa Bui
  • Selective Antisense Compounds and Uses Thereof
    Publication number: 20230113863
    Abstract: The present invention provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.
    Type: Application
    Filed: April 4, 2022
    Publication date: April 13, 2023
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Punit P. Seth, Michael Oestergaard, Eric E. Swayze
  • OLIGOMERIC COMPOUNDS COMPRISING BACKBONE CONSTRAINED MACROCYCLES
    Publication number: 20230095696
    Abstract: The present disclosure provides a trinucleotide comprising the formula below or an oligomeric compound comprising the formula below:
    Type: Application
    Filed: August 25, 2022
    Publication date: March 30, 2023
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Juan Carlos Salinas Hernandez, Stephen Hanessian, Eric E. Swayze, Punit P. Seth, Jenny Lorena Rico Duque, Graeme C. Freestone, Barbara Lugato, Rajasekaran Tamiselvan
  • Compositions and methods for modulating PKK expression
    Patent number: 11613752
    Abstract: Disclosed herein are antisense compounds and methods for decreasing PKK mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate PKK-associated diseases, disorders, and conditions.
    Type: Grant
    Filed: May 11, 2020
    Date of Patent: March 28, 2023
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventor: Eric E. Swayze
  • Modified Compounds and Uses Thereof
    Publication number: 20230068063
    Abstract: The present disclosure provides oligomeric compound comprising a modified oligonucleotide having a central region comprising one or more modifications. In certain embodiments, the present disclosure provides oligomeric compounds having an improved therapeutic index or an increased maximum tolerated dose.
    Type: Application
    Filed: March 17, 2022
    Publication date: March 2, 2023
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Punit P. Seth, Michael Oestergaard, Michael T. Migawa, Xue-hai Liang, Wen Shen, Stanley T. Crooke, Eric E. Swayze
  • Compositions for modulating Tau expression
    Patent number: 11591595
    Abstract: Disclosed herein are antisense compounds and methods for decreasing Tau mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate Tau-associated diseases, disorders, and conditions.
    Type: Grant
    Filed: August 6, 2020
    Date of Patent: February 28, 2023
    Assignee: Biogen MA Inc.
    Inventors: Holly Kordasiewicz, Eric E. Swayze, Susan M. Freier, Huynh-Hoa Bui
  • COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION
    Publication number: 20230057718
    Abstract: The present embodiments provide methods, compounds, and compositions for treating, preventing, or ameliorating a disease associated with dysregulation of the complement alternative pathway by administering a Complement Factor B (CFB) specific inhibitor to a subject.
    Type: Application
    Filed: May 7, 2021
    Publication date: February 23, 2023
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Tamar R. Grossman, Michael L. McCaleb, Andrew T. Watt, Susan M. Freier
  • MODULATORS OF DIACYGLYCEROL ACYLTRANSFERASE 2 (DGAT2)
    Publication number: 20230047452
    Abstract: The present embodiments provide methods, compounds, and compositions useful for inhibiting DGAT2 expression, which may be useful for treating, preventing, or ameliorating a disease associated with DGAT2.
    Type: Application
    Filed: February 22, 2022
    Publication date: February 16, 2023
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Sanjay Bhanot, Susan M. Freier, Eric E. Swayze
  • Oligomeric compounds comprising bicyclic nucleotides and uses thereof
    Patent number: 11566245
    Abstract: The present invention provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.
    Type: Grant
    Filed: January 21, 2020
    Date of Patent: January 31, 2023
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Eric E. Swayze
  • SELECTIVE ANTISENSE COMPOUNDS AND USES THEREOF
    Publication number: 20230002763
    Abstract: The present invention provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount, activity, or expression of the target nucleic acid in a cell. In certain embodiments, hybridization results in selective modulation of the amount, activity, or expression of a target Huntingtin gene or Huntingtin transcript in a cell.
    Type: Application
    Filed: January 27, 2022
    Publication date: January 5, 2023
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Michael Oestergaard, Punit P. Seth, Eric E. Swayze